![William E. Yelle](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
William E. Yelle
Founder at Firecyte Therapeutics, Inc.
Profile
William E.
Yelle is the founder of Firecyte Therapeutics, Inc. He is currently the Executive Chairman at Envisia Therapeutics, Inc. He was previously the Chief Executive Officer & Director at Aldea Pharmaceuticals, Inc. and the Vice President-Business Development at Sumitomo Pharma America, Inc. Yelle holds a graduate degree from the University of California, Berkeley, an undergraduate degree from the University of Massachusetts, and an MBA from Columbia Business School.
William E. Yelle active positions
Companies | Position | Start |
---|---|---|
Envisia Therapeutics, Inc.
![]() Envisia Therapeutics, Inc. BiotechnologyHealth Technology Envisia Therapeutics, Inc. develops novel ocular therapies. It provides glaucoma drug therapies that include PRINT particle therapeutics to overcome biologic and chemical. The company was founded by 2013 is headquartered in Morrisville, NC. | Chairman | - |
Firecyte Therapeutics, Inc.
![]() Firecyte Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Firecyte Therapeutics, Inc. is an emerging biotechnology company based in Cambridge, MA that is focused on developing novel treatment strategies for progressive neurodegenerative diseases of the eye. The company's research is centered around the role of microglia and neuroinflammation in these diseases. The team is led by Jonathan Levenson, the Chief Scientific Officer, who has over 16 years of experience in neuropsychiatry, neurodegeneration, and neuroinflammation. The company was founded by Dong Feng Chen and William E. Yelle, who has been the CEO since incorporation. | Founder | - |
Former positions of William E. Yelle
Companies | Position | End |
---|---|---|
Aldea Pharmaceuticals, Inc.
![]() Aldea Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aldea Pharmaceuticals, Inc. develops novel enzyme activators to enhance the removal of toxic aldehydes. It targets Aldehyde metabolism dysfunction which is associated with a variety of diseases from acute alcohol toxicity to orphan indications such as Fanconi anemia. The company was founded by Daria Mochly-Rosen, Che-Hong Chen and Wenjin Yang in 2011 and is headquartered in Redwood City, CA. | Chief Executive Officer | - |
Sumitomo Pharma America, Inc.
![]() Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 1984 and is headquartered in Marlborough, MA. | Corporate Officer/Principal | - |
Training of William E. Yelle
Columbia Business School | Masters Business Admin |
University of California, Berkeley | Graduate Degree |
University of Massachusetts | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 4 |
---|---|
Sumitomo Pharma America, Inc.
![]() Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 1984 and is headquartered in Marlborough, MA. | Health Technology |
Aldea Pharmaceuticals, Inc.
![]() Aldea Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aldea Pharmaceuticals, Inc. develops novel enzyme activators to enhance the removal of toxic aldehydes. It targets Aldehyde metabolism dysfunction which is associated with a variety of diseases from acute alcohol toxicity to orphan indications such as Fanconi anemia. The company was founded by Daria Mochly-Rosen, Che-Hong Chen and Wenjin Yang in 2011 and is headquartered in Redwood City, CA. | Health Technology |
Envisia Therapeutics, Inc.
![]() Envisia Therapeutics, Inc. BiotechnologyHealth Technology Envisia Therapeutics, Inc. develops novel ocular therapies. It provides glaucoma drug therapies that include PRINT particle therapeutics to overcome biologic and chemical. The company was founded by 2013 is headquartered in Morrisville, NC. | Health Technology |
Firecyte Therapeutics, Inc.
![]() Firecyte Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Firecyte Therapeutics, Inc. is an emerging biotechnology company based in Cambridge, MA that is focused on developing novel treatment strategies for progressive neurodegenerative diseases of the eye. The company's research is centered around the role of microglia and neuroinflammation in these diseases. The team is led by Jonathan Levenson, the Chief Scientific Officer, who has over 16 years of experience in neuropsychiatry, neurodegeneration, and neuroinflammation. The company was founded by Dong Feng Chen and William E. Yelle, who has been the CEO since incorporation. | Commercial Services |
- Stock Market
- Insiders
- William E. Yelle